biostudies-literatureTeofilo EBristol-Myers Squibb (France)17-28https://www.ebi.ac.uk/biostudies/studies/S-EPMC4975100biostudies-literatureUnknown17(1)<h4>Background</h4>Boosted protease inhibitors (PIs), including ritonavir-boosted atazanavir (ATV/r), are a recommended option for the initial treatment of HIV-1 infection based upon clinical trial data; however, long-term real-life clinical data are limited.<h4>Objective</h4>We evaluated the long-term use of ATV/r as a component of antiretroviral combination therapy in the real-life setting in the REMAIN study.<h4>Methods</h4>This was an observational cohort study conducted at sites across Germany, Portugal, and Spain. Retrospective historical and prospective longitudinal follow-up data were extracted every six months from medical records of HIV-infected treatment-naïve patients aged ≥ 18 years initiating a first-line ATV/r-containing regimen.<h4>Results</h4>Eligible patients (n = 517) weHIV clinical trialsLong-Term Efficacy, Tolerability, and Renal Safety of Atazanavir/Ritonavir-based Antiretroviral Therapy in a Cohort of Treatment-Naive Patients with HIV-1 Infection: the REMAIN Study.PMC4975100Not applicableMuller MJimenez-Exposito MJde Vilanova AKarcher HTeofilo EGermano IFreiwald MAntela AMocho LGonzalez EOJessen Hde Suso MTPernia ATLauenroth-Mai EMoreno Guillen SBarros Cde Almeida JRevuelta JALiano JPValente CREMAIN study groupVieira RFernandez PESantos CCid JFTavares LGolz JSchlote FMauss SAleixo MJAlmeida LStoehr AGonzalez JSRocha-Pereira NSerrao RSchnaitmann EMayr CBaumgarten ASanmartin LFSantos JFreud HKKern WVMansinho KMeurer ASierra JOGarcia JEComerma EDJimenez MCAmeida ISala BCFerrer VFStellbrink HJTurmstraße PSchuster DUrbano JPedrol PDKnechten HVera JAldeguer JLde Orta GPerez DGKuhlmann BCordes CAudebert FRausch MOliveira CRoxo FfalseLong-Term Efficacy, Tolerability, and Renal Safety of Atazanavir/Ritonavir-based Antiretroviral Therapy in a Cohort of Treatment-Naive Patients with HIV-1 Infection: the REMAIN Study.<h4>Background</h4>Boosted protease inhibitors (PIs), including ritonavir-boosted atazanavir (ATV/r), are a recommended option for the initial treatment of HIV-1 infection based upon clinical trial data; however, long-term real-life clinical data are limited.<h4>Objective</h4>We evaluated the long-term use of ATV/r as a component of antiretroviral combination therapy in the real-life setting in the REMAIN study.<h4>Methods</h4>This was an observational cohort study conducted at sites across Germany, Portugal, and Spain. Retrospective historical and prospective longitudinal follow-up data were extracted every six months from medical records of HIV-infected treatment-naïve patients aged ≥ 18 years initiating a first-line ATV/r-containing regimen.<h4>Results</h4>Eligible patients (n = 517) we2016-01-01T00:00:00Z2016 Feb2025-04-25T19:00:48.156Z2019-03-27T02:20:03ZS-EPMC49751002689953910.1080/15284336.2015.1112494